Tumor suppressive role of miR-194-5p in glioblastoma multiforme

Zhang,Zhao; Lei,Bo; Wu,Honggang; Zhang,Xiaoli; Zheng,Niandong

doi:10.3892/mmr.2017.7826

Tumor suppressive role of miR-194-5p in glioblastoma multiforme

Authors:
- Zhao Zhang
- Bo Lei
- Honggang Wu
- Xiaoli Zhang
- Niandong Zheng
View Affiliations

Affiliations: Department of Neurosurgery, The People's Hospital of Leshan City, Leshan, Sichuan 614000, P.R. China
Published online on: October 19, 2017 https://doi.org/10.3892/mmr.2017.7826
Pages: 9317-9322
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is defined by the World Health Organization as the most aggressive form of grade IV glioma, characterized by unrestrained cellular proliferation. microRNAs (miRs) serve important roles in the pathogenesis of GBM. However, the function of miR‑194‑5p in GBM remains unknown. In the present study, the miR‑194‑5p levels in GBM tissues and cells were evaluated using the reverse transcription‑quantitative polymerase chain reaction. Cellular proliferation was tested by MTT analysis. Cellular apoptosis was analyzed by fluorescence‑activated cell sorting. The protein level of insulin‑like growth factor 1 receptor, the target gene of miR‑194‑5p, was evaluated by western blotting. The interaction between miR‑194‑5p and the target gene was confirmed by the dual‑luciferase reporter assay. It was demonstrated that miR‑194‑5p inhibited cell growth and promoted apoptosis. In conclusion, the results of the present study indicated the tumor suppressive role of miR‑194‑5p.

View Figures

View References

1	Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ramakrishna R and Pisapia D: Recent molecular advances in our understanding of glioma. Cureus. 7:e2872015.PubMed/NCBI
5	Fisher JL, Schwartzbaum JA, Wrensch M and Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–90, vii. 2007. View Article : Google Scholar : PubMed/NCBI
6	Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO and Cairncross JG; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, ; National Cancer Institute of Canada Clinical Trials Group, : Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 11:165–180. 2006. View Article : Google Scholar : PubMed/NCBI
7	Oermann E, Collins BT, Erickson KT, Yu X, Lei S, Suy S, Hanscom HN, Kim J, Park HU, Eldabh A, et al: CyberKnife^® enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures. J Hematol Oncol. 3:222010. View Article : Google Scholar : PubMed/NCBI
8	Ottenhausen M, Krieg SM, Meyer B and Ringel F: Functional preoperative and intraoperative mapping and monitoring: Increasing safety and efficacy in glioma surgery. Neurosurg Focus. 38:E32015. View Article : Google Scholar : PubMed/NCBI
9	Paw I, Carpenter RC, Watabe K, Debinski W and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett. 362:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
10	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
11	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:pp. 10513–10518. 2008; View Article : Google Scholar : PubMed/NCBI
12	Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
14	Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haastert RJ, et al: Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget. 5:6687–6700. 2014. View Article : Google Scholar : PubMed/NCBI
15	Hwang H and Mendell J: microRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
16	Frankel LB, Wen J, Lees M, Høyer-Hansen M, Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent inhibitor of autophagy. EMBO J. 30:4628–4641. 2011. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Li Y and Lai M: The microRNA network and tumor metastasis. Oncogene. 29:937–948. 2010. View Article : Google Scholar : PubMed/NCBI
18	Dontula R, Dinasarapu A, Chetty C, Pannuru P, Herbert E, Ozer H and Lakka SS: microRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9 signaling. Genes cancer. 4:285–296. 2013. View Article : Google Scholar : PubMed/NCBI
19	LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
20	Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L and Luu HH: Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2:13–25. 2015. View Article : Google Scholar : PubMed/NCBI
21	Maris C, D'Haene N, Trépant AL, Le Mercier M, Sauvage S, Allard J, Rorive S, Demetter P, Decaestecker C and Salmon I: IGF-IR: A new prognostic biomarker for human glioblastoma. Br J Cancer. 113:729–737. 2015. View Article : Google Scholar : PubMed/NCBI
22	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Vermes I, Haanen C, Steffens-Nakken H and Reutellingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
25	Song B, Zhang C, Li G, Jin G and Liu C: miR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget. 7:13139–13152. 2016. View Article : Google Scholar : PubMed/NCBI
27	Josephs DH, Bax HJ and Karagiannis SN: Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci (Elite Ed). 7:293–308. 2015.PubMed/NCBI
28	Seton-Rogers S: Tumour microenvironment: Teaching old macrophages new tricks. Nat Rev Cancer. 13:7532013. View Article : Google Scholar : PubMed/NCBI
29	Ruffell B and Coussens LM: Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
30	Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846–859. 2014. View Article : Google Scholar : PubMed/NCBI
31	Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, et al: Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 373:428–437. 2015. View Article : Google Scholar : PubMed/NCBI
32	Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 352:aad30182016. View Article : Google Scholar : PubMed/NCBI